Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck (NYSE: MRK) said that the FDA issued a CRL about gefapixant. These are the details.

Merck (MRK): FDA Requests More Information About Gefapixant

AbbVie

CVS Health

Not only is the price right for these three healthcare stocks, but they all offer revenue growth along with an above-average dividend.

3 No-Brainer Healthcare Stocks to Buy Right Now for Less than $150

Shares of Merck & Co. Inc. MRK, -0.95% gained 0.4% in premarket trading on Monday after the company said the Food and Drug Administration requested additional information about its experimental cough treatment. The regulator issued a complete response letter asking for more data about the measurement of efficacy for gefapixant, Merck's investigational therapy for refractory or unexplained chronic cough.

Merck says FDA wants more information about its experimental cough treatment

The FDA has issued a Complete Response Letter (CRL) to Merck Co & Inc's (NYSE: MRK) gefapixant for refractory chronic cough (RCC) or unexplained chronic cough (UCC) in adults. Gefapixant is an investigational, non-narcotic, orally administered selective P2X3 receptor antagonist.

Merck's Gefapixant For Chronic Cough Slapped With FDA Complete Response Letter

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Provides U.S. and Japan Regulatory Update for Gefapixant

Merck Provides U.S. and Japan Regulatory Update for Gefapixant

Bloomberg reported that Merck & Co Inc (NYSE: MRK) has won a long-running legal battle to force its insurer to cover the costs of damages caused by the NotPetya' ransomware' attacks. Merck and its insurers have been battling over $1.4 billion in losses from the attack in 2017 after filing a lawsuit seeking to reclaim financial losses from the "NotPetya" incident.

Merck Scores Win In Insurance Battle Over Cyberattack - Bloomberg Report

KENILWORTH, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Phase 3 Results of KEYNOTE-775/Study 309 Trial KEYTRUDA Plus LENVIMA in Advanced Endometrial Carcinoma Published in New England Journal of Medicine

Results From Pivotal Phase 3 KEYNOTE-775/Study 309 Trial of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Frank Clyburn to Leave Merck

Frank Clyburn to Leave Merck

Merck & Co Inc (NYSE: MRK) has posted the final results from the Phase 3 trial of Keytruda (pembrolizumab) plus best supportive care (BSC) in previously treated hepatocellular carcinoma (HCC) patients. Keytruda slashed the risk of death by 21% over placebo in hepatocellular carcinoma patients in Asia who had previously received sorafenib.

Merck's Keytruda Manages To Cross The Finish Line In Liver Cancer Confirmatory Trial

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Significantly Improved Overall Survival (OS) in Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib

Merck's KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib

MADISON, N.J., Jan. 18, 2022 /PRNewswire/ -- Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J.

Merck Animal Health's Third Veterinarian Wellbeing Study Reveals Increased Health Challenges and Psychological Distress Among Veterinarians

Merck MRK, +0.07% and partner privately held Ridgeback Biotherapeutics said Tuesday they have won a supply agreement from the United Nations Children's Fund, or Unicef, to provide it with up to 3 million doses of their COVID-19 antiviral molnupiravir in the first half of 2022. The doses will be distributed in more than 100 low and middle-income countries following regulatory authorizations.

Merck and Ridgeback Biotherapeutics to supply 3 million doses of COVID antiviral to Unicef in 2022

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)---- $MRK #MRK--Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine

Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine

Pfizer

Roche Holding AG

Drug/biotech and medical device companies are likely to remain in the spotlight in 2022. Among the large drugmakers Roche (RHHBY), Pfizer (PFE), AbbVie (ABBV), and Merck (MRK) are worth retaining in your portfolio.

4 Large-Cap Drugmaker Stocks to Watch Despite Omicron Woes

The two oral COVID-19 therapies use completely different mechanisms to fight the coronavirus.

How Do Pfizer's and Merck's COVID Pills Work?

Caterpillar

Centennial Resource Development

Civitas Resources

Dow Inc

Honeywell

Intel

Intrepid Potash

Brigham Minerals

ProPetro Hld

Trillium Therapeutics

Verizon

Two sample Breakout Stocks for Week 3 with better than 10% short-term upside potential and a Dow stock pick. This past week was a negative momentum signal and no picks beat 10% peak gains with the picks down -0.08% in total led by TDW +4% and HXL +2.1%.

Week 3 MDA Breakout Stocks - January 2022: Short-Term Picks To Give You An Edge

The company's blockbuster cancer drug Keytruda was approved in Japan to treat patients with certain types of endometrial cancer.

Merck Snags Yet Another Indication for This Drug Combo

Merck is a large pharmaceutical company with a diversified portfolio of approved medications, and many drugs under clinical trials. Merck's Keytruda is one of the best-selling medications, and an important alternative to chemotherapy for a growing number of cancers.

Adding Merck To My High Quality Pharma Holdings

Merck (MRK) closed the most recent trading day at $81.20, moving -0.58% from the previous trading session.

Merck (MRK) Stock Sinks As Market Gains: What You Should Know

Merck's (MRK) phase III study evaluating Keytruda for adjuvant stage IB-IIIA non-small cell lung cancer (NSCLC) meets one of its dual primary endpoints of disease-free survival (DFS).

Merck (MRK) Keytruda Betters Survival in Adjuvant Lung Cancer

Gilead Sciences

Gilead (GILD) and Merck collaborate to evaluate the former's breast cancer drug in combination with the latter's blockbuster drug Keytruda for NSCLC study.

Gilead (GILD) Partners With Merck for Keytruda in NSCLC Study

We think that Bristol Myers Squibb stock (NYSE: BMY) currently is a better pick compared to its industry peer, Merck stock (NYSE: MRK), given its better growth prospects and comparatively lower valuation, with its stock trading at 3.0x trailing revenues, compared to 3.6x for MRK stock.

Here's A Better Pharmaceutical Pick Over Merck Stock

Merck & Co., Inc. (MRK) CEO Rob Davis Presents at 40th Annual J.P. Morgan Healthcare Conference (Transcript)

Absci Corp

Absci (ABSI) signs a deal with Merck for using its AI-powered drug creation platform to produce enzymes for Merck's biomanufacturing applications with an option for the development of three novel drugs.

Absci (ABSI) Inks Research Agreement With Merck, Stock Up

Merck & Co Inc (NYSE: MRK) has announced that the Phase 3 KEYNOTE-091 trial, investigating Keytruda, met one of its dual primary endpoints in NSCLC patients following surgical resection regardless of PD-L1 expression. Adjuvant treatment with Keytruda resulted in a statistically significant and clinically meaningful improvement in disease-free survival (DFS) compared with placebo in stage IB-IIIA non-small cell lung cancer (NSCLC).

News for Merck Stock (MRK)